Clearing the path for MRD as early endpoint in multiple myeloma – The Cancer Letter
In 2009, Carl Ola Landgren noticed that nearly all of his multiple myeloma patients were responding to the state-of-the-art drugs he was giving them at the NCI clinical center in Building 10 in Bethesda. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now […]